NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stall prostate cancer in chinese men
Disease control CompletedThis study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, po…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug cocktail shows promise in slowing advanced prostate cancer
Disease control CompletedThis study tested a combination of abiraterone acetate and prednisone in 131 men with advanced prostate cancer that had not yet spread on scans. The goal was to see if the drugs could lower PSA levels and delay cancer progression. Participants took daily pills alongside standard …
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Janssen Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cocktail of immune drugs shows promise for tough prostate cancer
Disease control CompletedThis study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC